Table 2. Univariate and multivariate analyses for overall survival of CCA patients.
| Variables | Univariate analysis | Multivariate analysis | ||||
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Age (years) | ||||||
| ≥ 60 vs. < 60 | 1.365 | 0.741-2.517 | 0.318 | |||
| Gender | ||||||
| Male vs. Female | 1.248 | 0.695-2.239 | 0.458 | |||
| Tumor location | ||||||
| Extrahepatic vs. Intrahepatic | 1.313 | 0.694-2.486 | 0.402 | |||
| Histological type | ||||||
| Adenocarcinoma vs. Non-adenocarcinoma | 1.366 | 0.537-3.473 | 0.513 | |||
| Differentiation grade | ||||||
| Poor/undifferentiated vs. Well/moderate | 1.646 | 0.910-2.978 | 0.099 | |||
| Serum CA19-9 level | ||||||
| > 37 U/ml vs. ≤ 37 U/ml | 1.486 | 0.819-2.697 | 0.193 | |||
| TNM stage | ||||||
| III-IV vs. I-II | 2.024 | 1.132-3.620 | 0.017* | 2.193 | 1.223-3.932 | 0.008** |
| Lymph node invasion | ||||||
| Yes vs. No | 1.884 | 1.025-3.463 | 0.041* | 1.784 | 0.959-3.318 | 0.067 |
| ZEB1-AS1 expression | ||||||
| Low vs. High | 2.220 | 1.202-4.101 | 0.011* | 2.569 | 1.355-4.870 | 0.004** |
Note. *P < 0.05, **P < 0.01. CCA, cholangiocarcinoma; HR, hazard ratio; CI, confidence interval; ZEB1-AS1, Zinc finger E-box binding homeobox 1 antisense 1.